Abstract 71P
Background
Ovarian cancer is the most common cause of death from gynecological malignancies. In the early stages, women are generally asymptomatic or have non-specific symptoms, making early-stage ovarian cancer undiagnosed. The different investigations reported the effect of polymorphisms in folate metabolism genes on ovarian cancer risk in different ethnicities. The aim of the current study was to analyze associations between the polymorphisms of key folate metabolism enzyme genes, methylene tetrahydrofolate reductase (MTHFR) and 5,10-methylenetetrahydrofolate dehydrogenase (MTHFD1) (C677T and G1958A, respectively) and ovarian cancer risk in Georgia. In addition, we assessed DNA methylation levels in ovarian cancer patients with polymorphic variants of these genes.
Methods
30 cancer patients and 30 healthy controls were included in this study. All patients and controls provided informed consent before being enrolled in the study. This study was approved by the Ethics Committee of the Tbilisi State Medical University. Genomic DNA was isolated from peripheral blood using a commercial kit (Qiagen, USA). Single Nucleotide Polymorphism (SNP) genotyping was performed using TaqMan Assay (Thermo Scientific, USA). Global DNA methylation was analyzed using the Global DNA Methylation Assay Kit (Abcam, MA, USA).
Results
The results suggest that there was a high association between MTHFD1 gene G1958A variant and the risk of ovarian cancer in Georgian patients (p<0.001). No statistically significant differences in allele and genotype frequencies of MTHFR gene C677T SNP were observed between patients and controls (p > 0.05). In addition, global DNA methylation in individuals with CT+TT genotypes were found to be reduced compared to CC genotypes in respect to the C677T variant of MTHFR gene.
Conclusions
In our study, we did not find any association between the MTHFR gene C677T polymorphism and ovarian cancer, however the AA genotype of MTHFD1 gene G1958A variant associated with increased risk of ovarian cancer. We, also, found that CT and TT genotypes of MTHFR gene C677T variant are associated with altered DNA methylation in ovarian cancer patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
This study was supported by the Shota Rustaveli National Science Foundation of Georgia (grant number #FR-21-17599).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract